Overview
This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.
Description
Neoadjuvant therapy with experimental treatment followed by surgery.
Eligibility
Inclusion Criteria:
- Resectable NSQ NSCLC
- Age 18-65 years
- male or female
- ECOG 0-1
- Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer
- Subjects must have adequate pulmonary function for the intended pneumonectomy;
Exclusion Criteria:
- SCLC or SQ NSCLC
- previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc.
- patients who have previously used anti-angiogenic drugs;
- allergic to any component of the study drug or chemotherapy drugs
- patients with any severe and or uncontrolled disease